Medis El to reacquire US rights to CellScan:
This article was originally published in Clinica
Executive Summary
Israeli diagnostic company Medis El has the option to reacquire the US distribution rights to CellScan under an agreement with US shareholder Cell Diagnostics (CDI). Medis will receive $500,000 from CDI on July 1st, as the first repayment of a $2.5 million note. Medis will cancel the unpaid $2 million if it exercises the option to CellScan. Medis says the US rights will be an asset in its search for an international marketing partner for the cancer screening system.